Wire · opportunities
FDA Approves Durvalumab With Enfortumab Vedotin for MIBC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
The FDA approved durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab for muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin chemotherapy, based on improved event-free and overall survival in the VOLGA trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it.
◆ ◆ The Wire takeaway
You now have a new FDA-approved drug combo for MIBC that opens a path to market if cisplatin chemo is off the table. Clinical-stage biotech founders in oncology must fast-track strategies around durvalumab and enfortumab vedotin use.
◆ Coverage
6 sources · 13 Nov 2026
◆ Related on Wire
◆ Topics